case_images: PMC8542851_01
case_images: (A) The blood cell and PCM1-JAK2 fusion transcript changes in patient 1 over the course of the disease. (B) The blood cell changes in patient 2 over the course of the disease. WBC, white blood cells; HB, hemoglobin; PLT, platelet; Eo, eosinophils.
case_images: fonc-11-753842-g001.jpg
case_images: PMC8542851_02_fonc-11-753842-g001.jpg
case_images: f1
case_images: In short, the patient cannot tolerate the therapeutic dose of ruxolitinib and is preparing for allo-HSCT ( Figure 1B ).
case_images: PMC8542851_02
case_images: (A) The blood cell and PCM1-JAK2 fusion transcript changes in patient 1 over the course of the disease. (B) The blood cell changes in patient 2 over the course of the disease. WBC, white blood cells; HB, hemoglobin; PLT, platelet; Eo, eosinophils.
case_images: fonc-11-753842-g001.jpg
case_images: PMC8542851_02_fonc-11-753842-g001.jpg
case_images: f1
case_images: In short, the patient cannot tolerate the therapeutic dose of ruxolitinib and is preparing for allo-HSCT ( Figure 1B ).